Page last updated: 2024-11-03

riluzole and Degenerative Diseases, Central Nervous System

riluzole has been researched along with Degenerative Diseases, Central Nervous System in 11 studies

Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.

Research Excerpts

ExcerptRelevanceReference
"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission."8.02Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021)
"Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients."5.46Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017)
" Riluzole is the only drug approved by the US Food and Drug Administration for amyotrophic lateral sclerosis."4.98The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis. ( Liu, J; Wang, LN, 2018)
"Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease commonly treated with riluzole, a small molecule that may act via modulation of glutamatergic neurotransmission."4.02Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis. ( Atkin, JD; Berning, BA; Blizzard, CA; Chung, RS; Della Gatta, PA; Gul, H; Hedl, TJ; Jacobs, KR; Keating, SS; Le, S; Lee, A; Mehta, P; Morsch, M; Riddell, WR; San Gil, R; Shi, B; Venturato, J; Walker, AK; Watson, O; Wright, AL, 2021)
" Riluzole is used for the treatment of amyotrophic lateral sclerosis and reported to have neuroprotective effects in animal models of Parkinson's disease, Huntington's disease, and brain ischemia."3.72Riluzole enhances glutamate uptake in rat astrocyte cultures. ( Dalcin, KB; Dall'Onder, LP; Frizzo, ME; Souza, DO, 2004)
"Amyotrophic Lateral Sclerosis is a neurodegenerative disease caused by progressive loss of motor neurons, which severely compromises skeletal muscle function."2.82Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle. ( Camerino, GM; Canfora, I; Pierno, S; Tarantino, N, 2022)
"Riluzole is an antiglutamatergic agent and the only drug to offer some effect on the life expectancy of ALS patients."1.46Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam. ( Andreasen, SR; Christensen, TB; Holm, MM; Lundbye, CJ; Schmitt-John, T; Thielsen, KD, 2017)

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's2 (18.18)24.3611
2020's4 (36.36)2.80

Authors

AuthorsStudies
Tarantino, N1
Canfora, I1
Camerino, GM1
Pierno, S1
Wong, C1
Dakin, RS1
Williamson, J1
Newton, J1
Steven, M1
Colville, S1
Stavrou, M1
Gregory, JM1
Elliott, E1
Mehta, AR1
Chataway, J1
Swingler, RJ1
Parker, RA1
Weir, CJ1
Stallard, N1
Parmar, MKB1
Macleod, MR1
Pal, S1
Chandran, S1
Pinard, M3
Dastpeyman, S3
Poitras, C3
Bernard, G3
Gauthier, MS3
Coulombe, B3
Wright, AL1
Della Gatta, PA1
Le, S1
Berning, BA1
Mehta, P1
Jacobs, KR1
Gul, H1
San Gil, R1
Hedl, TJ1
Riddell, WR1
Watson, O1
Keating, SS1
Venturato, J1
Chung, RS1
Atkin, JD1
Lee, A1
Shi, B1
Blizzard, CA1
Morsch, M1
Walker, AK1
Andreasen, SR1
Lundbye, CJ1
Christensen, TB1
Thielsen, KD1
Schmitt-John, T1
Holm, MM1
Liu, J1
Wang, LN1
Yang, J1
Bridges, K1
Chen, KY1
Liu, AY1
Cifra, A1
Nani, F1
Sharifullina, E1
Nistri, A1
Sanacora, G1
Frizzo, ME1
Dall'Onder, LP1
Dalcin, KB1
Souza, DO1
Fumagalli, E1
Bigini, P1
Barbera, S1
De Paola, M1
Mennini, T1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Motor Neurone Disease - Systematic Multi-Arm Adaptive Randomised Trial[NCT04302870]Phase 2/Phase 3800 participants (Anticipated)Interventional2020-02-27Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

3 reviews available for riluzole and Degenerative Diseases, Central Nervous System

ArticleYear
Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle.
    Cells, 2022, 01-25, Volume: 11, Issue:3

    Topics: Amyotrophic Lateral Sclerosis; Humans; Ion Channels; Muscle, Skeletal; Neurodegenerative Diseases; R

2022
The efficacy and safety of riluzole for neurodegenerative movement disorders: a systematic review with meta-analysis.
    Drug delivery, 2018, Volume: 25, Issue:1

    Topics: Amyotrophic Lateral Sclerosis; Humans; Neurodegenerative Diseases; Neuroprotective Agents; Randomize

2018
Do glutamatergic agents represent a new class of antidepressant drugs? Part 1.
    The Journal of clinical psychiatry, 2009, Volume: 70, Issue:10

    Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Disease Models, Animal; Drug Design; Hum

2009

Trials

1 trial available for riluzole and Degenerative Diseases, Central Nervous System

ArticleYear
Motor Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-controlled trial of repurposed drugs in motor neuron disease.
    BMJ open, 2022, 07-07, Volume: 12, Issue:7

    Topics: Amyotrophic Lateral Sclerosis; Double-Blind Method; Humans; Memantine; Motor Neuron Disease; Neurode

2022

Other Studies

7 other studies available for riluzole and Degenerative Diseases, Central Nervous System

ArticleYear
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
    Molecular brain, 2022, 11-30, Volume: 15, Issue:1

    Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA

2022
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
    Molecular brain, 2022, 11-30, Volume: 15, Issue:1

    Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA

2022
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
    Molecular brain, 2022, 11-30, Volume: 15, Issue:1

    Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA

2022
Riluzole partially restores RNA polymerase III complex assembly in cells expressing the leukodystrophy-causative variant POLR3B R103H.
    Molecular brain, 2022, 11-30, Volume: 15, Issue:1

    Topics: DNA-Directed RNA Polymerases; Humans; Mutation, Missense; Neurodegenerative Diseases; Riluzole; RNA

2022
Riluzole does not ameliorate disease caused by cytoplasmic TDP-43 in a mouse model of amyotrophic lateral sclerosis.
    The European journal of neuroscience, 2021, Volume: 54, Issue:6

    Topics: Amyotrophic Lateral Sclerosis; Animals; Disease Models, Animal; DNA-Binding Proteins; Female; Mice;

2021
Excitatory-inhibitory imbalance in the brain of the wobbler mouse model of amyotrophic lateral sclerosis substantiated by riluzole and diazepam.
    Neuroscience letters, 2017, Sep-29, Volume: 658

    Topics: Amyotrophic Lateral Sclerosis; Animals; Diazepam; Disease Models, Animal; Hippocampus; Mice, Inbred

2017
Riluzole increases the amount of latent HSF1 for an amplified heat shock response and cytoprotection.
    PloS one, 2008, Aug-06, Volume: 3, Issue:8

    Topics: Cell Survival; DNA-Binding Proteins; Excitatory Amino Acid Agonists; Genes, Reporter; Heat Shock Tra

2008
A repertoire of rhythmic bursting produced by hypoglossal motoneurons in physiological and pathological conditions.
    Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2009, Sep-12, Volume: 364, Issue:1529

    Topics: Action Potentials; Animals; Brain Stem; Glutamic Acid; Humans; Hydrogen Peroxide; Hypoglossal Nerve;

2009
Riluzole enhances glutamate uptake in rat astrocyte cultures.
    Cellular and molecular neurobiology, 2004, Volume: 24, Issue:1

    Topics: Animals; Animals, Newborn; Astrocytes; Brain Ischemia; Cells, Cultured; Dose-Response Relationship,

2004
Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease.
    Experimental neurology, 2006, Volume: 198, Issue:1

    Topics: Animals; Body Weight; Brain-Derived Neurotrophic Factor; CD11b Antigen; Cell Death; Choline O-Acetyl

2006